Emerging cardiovascular indications of mineralocorticoid receptor antagonists
- 1 April 2015
- journal article
- review article
- Published by Elsevier BV in Trends in Endocrinology & Metabolism
- Vol. 26 (4), 201-211
- https://doi.org/10.1016/j.tem.2015.01.007
Abstract
No abstract availableKeywords
This publication has 69 references indexed in Scilit:
- Beneficial Effects of Proanthocyanidins in the Cardiac Alterations Induced by Aldosterone in Rat Heart through Mineralocorticoid Receptor BlockadePLOS ONE, 2014
- Selection of a mineralocorticoid receptor antagonist for patients with hypertension or heart failureEuropean Journal of Heart Failure, 2013
- Rationale and design of ARTS: a randomized, double‐blind study of BAY 94‐8862 in patients with chronic heart failure and mild or moderate chronic kidney diseaseEuropean Journal of Heart Failure, 2012
- Eplerenone in Patients with Systolic Heart Failure and Mild SymptomsThe New England Journal of Medicine, 2011
- A New Mode of Mineralocorticoid Receptor Antagonism by a Potent and Selective Nonsteroidal Molecule*Published by Elsevier BV ,2010
- A Comparison of the Aldosterone‐blocking Agents Eplerenone and SpironolactoneClinical Cardiology, 2008
- Mechanisms of Mineralocorticoid ActionHypertension, 2005
- Mineralocorticoid Receptors: Distribution and ActivationHeart Failure Reviews, 2005
- Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial InfarctionThe New England Journal of Medicine, 2003
- The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart FailureThe New England Journal of Medicine, 1999